期刊文献+

融合蛋白LHRH-PE40与癌细胞表面LHRH受体结合的特性 被引量:7

Binding Ability of LHRH-PE40 to LHRH Receptors on Cancer Cell Line
在线阅读 下载PDF
导出
摘要 目的 :探讨重组毒素 LHRH- PE40与癌细胞表面 LHRH受体结合的特性。方法 :用放射性配基结合分析的方法测定亲和力和受体容量。结果 :LHRH- PE40与 Hela细胞的亲和力 :Kd=( 0 .36± 0 .1 2 ) nmol,容量 Bmax=( 0 .2 3± 0 .1 5 )μmol· g-1;与 Hep2细胞亲和力 :Kd=( 0 .33±0 .1 1 ) nmol,容量 Bmax=( 0 .46± 0 .1 2 ) μmol· g-1。结论 :重组毒素 LHRH- Objective: To evaluate the binding ability of LHRH PE40, a fusion protein, to the LHRH receptors on cancer cell line.Methods: The radioligand binding assay of receptors was used to calculate the Kd and B max . Results: Hela cell line: Kd=(0.36±0.12)nmol, B max =(0.23±0.15)μmol·g -1 ; Hep2 cell line: Kd=(0.33± 0.11)nmol , B max =(0.46±0.12)μmol·g -1 . Conclusion:LHRH PE40 has a high bingding affinity to the LHRH receptors on cancer cell line, which is the same as the natural LHRH.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2003年第1期5-8,共4页 Journal of Jilin University:Medicine Edition
基金 国家重点科技攻关计划专题项目 (96 - 90 1- 0 5 - 10 1)
关键词 LHRH-PE40 受体 细胞表面 放射性配基结合分析 受体亲和力 LHRH PE40 receptors,cell surface radioligand binding assay antibody affinity
  • 相关文献

参考文献1

二级参考文献14

  • 1Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarin tumors are identical with that found in pituitary[J]. Mol Cell Endocrinol, 1994, 106:145-149.
  • 2Imai A, Ohno T, Iida K, et al. Gonadotropin-releasing hormone receptor in gynecologic tumors[J]. Cancer, 1994, 74(9):2555-2561.
  • 3Kismanovic LZ, Stojilkovic SS, Mertz LM, et al. Expression of gonadotropin-releasing hormone receptors and autocrine regulation of neuropeptide release in immortalized hypothalamic neurons[J]. Proc Natl Acad Sci USA, 1993, 90:3908-3912.
  • 4Kakar SS, Jennes L. Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues[J]. Cancer lett, 1995, 98:57-62.
  • 5Pati D, Habibi HR. Inhibition of human hepatocarcinoma cell proliferation by mammalian and fish gonadotropin-releasing hormones[J]. Endocrinology, 1995, 136(1):75-84.
  • 6Qayum A, Gullick W, Clayton RC, et al. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors[J]. Br J Cancer, 1990, 62:96-99.
  • 7Yano T ,Korkut E, Pinski J, et al. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH[J]. Breast Cancer Res Treat, 1992, 21:35-45.
  • 8Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers[J]. Hum Reprod, 1994,9:1364-1379.
  • 9Srkalovic G, Schally AV, Wittliff JL, et al. Presence and characteristic of receptors for [D-Trp6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer[J]. Int J Oncol, 1998, 12:489-498.
  • 10Yano T, Pinski J, Radulovic S , et al. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone[J]. Proc Natl Acad Sci USA, 1994,91:1701-1705.

共引文献19

同被引文献84

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部